1. Home
  2. LZB vs MESO Comparison

LZB vs MESO Comparison

Compare LZB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LZB
  • MESO
  • Stock Information
  • Founded
  • LZB 1927
  • MESO 2004
  • Country
  • LZB United States
  • MESO Australia
  • Employees
  • LZB N/A
  • MESO N/A
  • Industry
  • LZB Home Furnishings
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LZB Consumer Discretionary
  • MESO Health Care
  • Exchange
  • LZB Nasdaq
  • MESO Nasdaq
  • Market Cap
  • LZB 1.6B
  • MESO 1.4B
  • IPO Year
  • LZB N/A
  • MESO N/A
  • Fundamental
  • Price
  • LZB $41.97
  • MESO $10.64
  • Analyst Decision
  • LZB Buy
  • MESO Buy
  • Analyst Count
  • LZB 2
  • MESO 4
  • Target Price
  • LZB $46.00
  • MESO $18.00
  • AVG Volume (30 Days)
  • LZB 322.4K
  • MESO 226.6K
  • Earning Date
  • LZB 06-16-2025
  • MESO 02-26-2025
  • Dividend Yield
  • LZB 2.10%
  • MESO N/A
  • EPS Growth
  • LZB 7.87
  • MESO N/A
  • EPS
  • LZB 2.91
  • MESO N/A
  • Revenue
  • LZB $2,091,871,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • LZB $3.42
  • MESO $178.09
  • Revenue Next Year
  • LZB $3.50
  • MESO $305.06
  • P/E Ratio
  • LZB $14.37
  • MESO N/A
  • Revenue Growth
  • LZB 1.80
  • MESO N/A
  • 52 Week Low
  • LZB $33.34
  • MESO $5.78
  • 52 Week High
  • LZB $48.31
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • LZB 49.38
  • MESO 40.85
  • Support Level
  • LZB $41.38
  • MESO $10.60
  • Resistance Level
  • LZB $43.27
  • MESO $11.26
  • Average True Range (ATR)
  • LZB 0.78
  • MESO 0.41
  • MACD
  • LZB -0.24
  • MESO -0.06
  • Stochastic Oscillator
  • LZB 8.68
  • MESO 12.00

About LZB La-Z-Boy Incorporated

La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; and Retail, which sells upholstered and case goods furniture to the end consumer. The majority of the company's revenue is derived from its Wholesale segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: